- NASDAQ: MRNA is set to extend its fall as rival AstraZeneca moves forward with large coronavirus trial.
- Concerns about Moderna Inc's low-temperature storage needs is also weighing on the stock.
- A probe by the US Department of Defense is a third adverse factor.
Update: NASDAQ: MRNA is set to extend its gains on Friday after rising on Thursday – defying the broader sell-off in stocks. The S&P 500 crashed by 3.5% as the White House is reportedly rushing through a coronavirus vaccine as early as October. Moderna is one of the leaders in the race, conducting a Phase 3 trial of its immunization candidate.
Buy every company reporting coronavirus-related progress – that seemed to be the modus operandi of investors in recent months. However, as time passes by, markets are separating the wheat from the chaff – taking a closer look at firms and often selling off shares.
That may be Moderna's case. The Massachusets-based pharmaceutical firm is at the forefront of developing COVID-19 immunization – but has run into a few hurdles.
Here are three MRNA downers:
1) AstraZeneca's trial: While Moderna Inc. is at an advanced stage of testing its coronavirus vaccine candidate, a project by the University of Oxford and AstraZeneca is not only considered the world leader – but also announced a broad 50,000-strong trial starting in the US. Investors may prefer picking a more significant contender.
2) Cold feet due to freezing needs: Reports suggest that Moderna's COVID-19 solution needs to be stored at extremely low temperatures. Keeping medicine in cool and dark places is not a novelty, but the need for additional care could make distribution more complicated. That may also keep Moderna behind.
3) DOD probe: The US Department of Defense is looking into a claim by Knowledge Ecology International that MRNA failed to disclose the use of government grants in its patent applications. That would be a violation of federal law. The investigation is at the best case a distraction from the urgent coronavirus project.
These three issues could further pressure Moderna Inc's shares.
MRNA Stock Price
NASDAQ: MRNA close Monday's session at $64.89 – the lowest since early July. At the time of writing, the equity is changing hands at $63.20 in pre-market trading, representing an additional fall of over 2%.
Critical support awaits at $62.60, the pre-surge August low, and then at $52.20. Resistance is at the recent peak of $70.50, followed by the 52-week high of $95.20 it reached when it announced a new and promising test.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD bounces off lows, retests 1.1370
Following an early drop to the vicinity of 1.1310, EUR/USD now manages to regain pace and retargets the 1.1370-1.1380 band on the back of a tepid knee-jerk in the US Dollar, always amid growing optimism over a potential de-escalation in the US-China trade war.
GBP/USD trades slightly on the defensive in the low-1.3300s
GBP/USD remains under a mild selling pressure just above 1.3300 on Friday, despite firmer-than-expected UK Retail Sales. The pair is weighed down by a renewed buying interest in the Greenback, bolstered by fresh headlines suggesting a softening in the rhetoric surrounding the US-China trade conflict.
Gold remains offered below $3,300
Gold reversed Thursday’s rebound and slipped toward the $3,260 area per troy ounce at the end of the week in response to further improvement in the market sentiment, which was in turn underpinned by hopes of positive developments around the US-China trade crisis.
Ethereum: Accumulation addresses grab 1.11 million ETH as bullish momentum rises
Ethereum saw a 1% decline on Friday as sellers dominated exchange activity in the past 24 hours. Despite the recent selling, increased inflows into accumulation addresses and declining net taker volume show a gradual return of bullish momentum.
Week ahead: US GDP, inflation and jobs in focus amid tariff mess – BoJ meets
Barrage of US data to shed light on US economy as tariff war heats up. GDP, PCE inflation and nonfarm payrolls reports to headline the week. Bank of Japan to hold rates but may downgrade growth outlook. Eurozone and Australian CPI also on the agenda, Canadians go to the polls.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.